A LinkedIn post from bwell Connected Health highlights a data quality case study in healthcare AI led by the company’s VP of Data Engineering. According to the post, the initiative reportedly produced a 122% improvement in a healthcare data quality score and 10x lower AI costs, while transforming at least one patient record from “dangerous to diagnostic.”
Memorial Day Sale – Claim 70% Off TipRanks
- Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
- Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
The post outlines a 13-step refinement process, a de-duplication strategy, and methods to address issues such as hallucinated drug interactions and missing diagnoses. For investors, the content suggests bwell is positioning its platform as an infrastructure layer for more reliable, lower-cost healthcare AI, which could enhance its value proposition to payers, providers, and digital health partners.
If these capabilities are validated at scale by customers, the described improvements could support pricing power, stickier deployments, and differentiated outcomes in risk-bearing contracts. More robust data quality tools may also open incremental revenue opportunities in data services and interoperability, in a market where healthcare AI adoption is accelerating but still constrained by fragmented and low-fidelity data.